T.TO 0.13ENB.TO 0.8BEP.UN.TO -1.15CP.TO 1.15VRT -19.67NVDA -7.33TSM -15.23JPM -6.1
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

27.72
-0.00 (0.00%)
as of Sep 14, 2026, 8:00:00 pm Market Open.
583 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconSep 14, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Pfizer Inc. (PFE) is perceived as a defensive stock with an attractive dividend yield around 6-7%, appealing to income-focused investors. However, many experts express concern about the company's growth potential following a reliance on COVID-19 vaccine revenues, which have receded. The consensus indicates that while PFE maintains a low valuation (PE around 8-10x), its growth is stagnant or uncertain due to impending patent expirations and the challenges associated with developing new blockbuster drugs. Moreover, there are worries that the ongoing focus on acquisitions may not lead to the anticipated revenue boosts. Despite these concerns, some analysts suggest PFE could still perform well for patient investors, especially as sector interest begins to build. Ultimately, the outlook remains cautious, with a preference noted for other stocks in the pharmaceutical sector that exhibit better growth trajectories.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
TOP PICK

Pfizer Inc(PFE)

Oct 08, 2009
Pharmaceutical industry has been very much out of favour. Likes the long-term play in pharmaceuticals with the aging population and demographics. Recently bought Wyeth (WYE-N) and expecting a lot of synergies from this. Trades at 8.5X earnings with almost 4% dividends.
Photo of Colin StewartColin Stewart
Owned
Unlock Rating
$16.70

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 11, 2009
Good performer in the last 6 to 7 months. Decent yield. Problem with all major pharma stocks are the products coming off patent requiring new avenues for growth. Acquired Wyeth (WYE-N), which has fewer drugs coming off patent and more coming on line. (Also owns Teva for their generic drugs.)
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$16.25

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 10, 2009
This will depend on what the US president comes up with on a healthcare plan. Until that is resolved all the drug stocks will be under pressure.
Photo of Peter BriegerPeter Brieger
No
Unlock Rating
$16.34

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 04, 2009
Largest drug company globally. Very strong number of products but along with most of the big pharmaceutical companies there are a large number of drugs that come off patent. About 25% of their earnings comes from one drug, Lipitor and when it comes off patent it will have a big effect on their earnings. There are better places to be.
Photo of Andrew Guy, CFAAndrew Guy, CFAUnlock Rating
$16.39

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 25, 2009
This is not the one to bet on in this sector. Very cheap, up for a reason. Drug pipeline is not impressive. Have patent issues. (See Top Picks.)
Photo of Karl BergerKarl Berger
No
Unlock Rating
$16.80

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Aug 19, 2009
Recently started buying through selling Put options, which would require him to Buy (e.g. at $16). Tide is turning on the sector and he likes it very much. Risks are healthcare reform and patent expirations.
Photo of Ara NalbandianAra Nalbandian
Owned
Unlock Rating
$16.37

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 27, 2009
There will continue to be pressure on prices. Also US government is litigation friendly, which can hit them with 1) injury related suits and 2) patent infringement.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$16.62

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Jul 07, 2009
Reflects all the bad news that Lipitor will be going going off patent in a couple of years and its drug pipeline is absolutely barren. In the meantime you get paid 6.5%. Pretty cheap.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$14.59

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jul 06, 2009
Thinks the pharmaceutical sector will start to do quite well in the next 2 years. It is so negative now in terms of what the government wants to do but historically they have never been able to cut the price of drugs. You are getting 5% to wait.
Photo of Kevin O'LearyKevin O'Leary
Owned
Unlock Rating
$14.57

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jun 12, 2009
Not a fan of big cap pharma and hasn't been for some time. One of the most difficult business models to operate. Regulatory issues are so difficult to overcome between patent expiries and increasingly stringent health regulations and registration processes. (See Top Picks.)
Photo of Charles LannonCharles Lannon
No
Unlock Rating
$14.76

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Jun 04, 2009
The major pharmaceuticals are not on his top list. Bioteches are where you are going to see innovations. They are the ones coming out with the new drugs and have a better pipeline.
Photo of Matthew McCallMatthew McCall
No
Unlock Rating
$14.64

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

May 06, 2009
Just doesn't seem to be up to right itself. Spinning off a lot of cash but its size limits it from growing.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$13.91

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 14, 2009
Getting killed by generics. They get sued when they hurt people. Government won't stand up for them when generics can provide health care at a fraction of the price. Prefer TEVA-O
Photo of David BaskinDavid Baskin
No
Unlock Rating
$13.34

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 31, 2009
Has been a difficult stock. Could improve from here however there will be other opportunities in this space you could get more juice from.
Photo of Brett HrybBrett Hryb
Owned
Unlock Rating
$13.62

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Mar 30, 2009
(A Top Pick April 10/08. Down 27.8%.) Paired with Teva (TEVA-Q) as his generic company. Down a little because of their intention to purchase Wyath. Cut their dividend but still gives a healthy yield. Good defensive place.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$13.70

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
Showing 481 to 495 of 890 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

TPZ.TO 0.13$12.73
KBL.TO 0.98$42.9
PPL.TO -0.14$66.12
AQN.TO 0.11$7.46
EMA.TO -0.02$68.17

Today's Top Picks

T.TO 0.13$12.73
ENB.TO 0.8$67.03
BEP.UN.T… -1.15$40.98
CP.TO 1.15$124.99
VRT -19.67$237.39

Popular Articles

Latest Sell Signals

CPX.TO 1.15$124.99
AVGO -17.27$344.72
APP 10.28$334.24
XRE.TO 0.05$15.73
ORCL -5.49$144.79

Most Recent Experts

Ryan Bushell

Ryan Bushell

Newhaven Asset Management

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

You may also like